New pricing policy for medicinal products

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

New pricing policy for medicinal products

In an effort to reduce pharmaceutical expenditure, the Greek government has recently introduced a new pricing policy for pharmaceutical products. The new provisions on pricing of pharmaceuticals were introduced by market decree 2 of March 31 2010.

According to the new pricing regulations, prices of originator products are based on the threelowest reference prices in all EU states for which official data is available. Under the new system these prices will be reviewed and updated 3 times a year. After patent expiry, prices of original products are reduced by 20%.

Generic products are priced up to a maximum of 72% of the respective price which the original medicinal product had during patent validity. Following patent expiry, the price of the generics will be set up to a maximum of 90% of the respective original product.

According to the Minister of Development the new regulations, which will affect the price of all medicines in the market, are expected to lower the prices by 20% to 25%. Under the former regime, generics were priced only at a 20% discount to the originators price, thus resulting, according to the Minister, in Greece being the third most expensive country in the world in generics.

The re-calculation of the price of all products in the market has proven to be a very difficult task causing a great delay in the issuance of the new price bulletin. Under pressure to take immediate action in price cuts, the Ministry issued a provisional price bulletin, with a flat reduction of prices. This however, has caused great concern to originator pharmaceutical companies who fear that reductions applied incorrectly may never be re-adjusted and may even result in drug shortages on the domestic market since low prices may fuel parallel exports. Legal action has been taken by an originator company who is challenging the price bulletin before the Supreme Court.

The impact of the new pricing regulations to the innovator and generic pharmaceutical industries in Greece should become clearer in the next few months.

kilimiris.jpg

Constantinos Kilimiris


Patrinos & Kilimiris

7, Hatziyianni Mexi Str.

GR-11528 Athens, Greece

Tel: +30210 7222906, 7222050

Fax: +30210 7222889

info@patrinoskilimiris.com

www.patrinoskilimiris.com

more from across site and SHARED ros bottom lb

More from across our site

Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Former Latham partner Chris Henry and transactions lawyer Liza Cotter are heading to the firm as Weil’s IP practice starts to disperse
Rival IP teams return to court for a closely watched appeal over AI and copyright, but observers hoping for answers to some of the technology’s biggest legal questions may be left disappointed
Eight years after its launch, members of the Australian patent firm’s Singapore office explain its growth strategy over the past year
Gift this article